CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Down 81.2% in July

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totaling 5,655 shares, a decline of 81.2% from the July 15th total of 30,057 shares. Based on an average trading volume of 329,145 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are short sold.

CytoMed Therapeutics Price Performance

NASDAQ GDTC traded up $0.01 during trading hours on Friday, hitting $0.86. The company’s stock had a trading volume of 3,712 shares, compared to its average volume of 266,024. The company’s 50 day simple moving average is $0.99 and its two-hundred day simple moving average is $1.01. CytoMed Therapeutics has a 12 month low of $0.68 and a 12 month high of $3.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.